FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387245569> ?p ?o ?g. }

• W4387245569 abstract "Mantle cell lymphoma (MCL) is an incurable B-cell non-Hodgkin's lymphoma and patients who relapse on targeted therapies have a poor prognosis. Protein arginine methyltransferase 5 (PRMT5), an enzyme essential for B-cell transformation, drives multiple oncogenic pathways and is overexpressed in MCL. Despite the anti-tumor activity of PRMT5 inhibition (PRT-382/PRT-808), drug resistance was observed in a patient derived xenograft (PDX) MCL model. Decreased survival of mice engrafted with these PRMT5 inhibitor resistant cells versus treatment-naïve cells was observed (p-value: 0.005). MCL cell lines showed variable sensitivity to PRMT5 inhibition. Using PRT-382, cell lines were classified as sensitive (n=4; IC50 20-140 nM) or primary resistant (n=4; 340-1650 nM). Prolonged culture of sensitive MCL lines with drug escalation produced PRMT5 inhibitor resistant cell lines (n=4; 200-500 nM). This resistant phenotype persisted after prolonged culture in the absence of drug and was observed with PRT-808. In the resistant PDX and cell line models, symmetric dimethylarginine reduction was achieved at the original PRMT5 inhibitor IC50 suggesting activation of alternative resistance pathways. Bulk RNA sequencing of resistant cell lines and PDX relative to sensitive or short-term treated cells, respectively, highlighted shared upregulation of multiple pathways including mTOR signaling (p-value &lt; 10-5 and z-score &gt;0.3 or &lt;0.3). Single cell RNA sequencing analysis demonstrated a strong shift in global gene expression with upregulation of mTOR signaling in resistant MCL PDX samples. Targeted blockade of mTORC1 with temsirolimus overcame the PRMT5 inhibitor resistant phenotype, displayed therapeutic synergy in resistant MCL cell lines, and improved survival of a resistant PDX." @default.
• W4387245569 created "2023-10-03" @default.
• W4387245569 creator A5000554189 @default.
• W4387245569 creator A5000870253 @default.
• W4387245569 creator A5006168813 @default.
• W4387245569 creator A5010045617 @default.
• W4387245569 creator A5011478803 @default.
• W4387245569 creator A5012097098 @default.
• W4387245569 creator A5012846289 @default.
• W4387245569 creator A5018193992 @default.
• W4387245569 creator A5021340844 @default.
• W4387245569 creator A5037733702 @default.
• W4387245569 creator A5038777438 @default.
• W4387245569 creator A5041781866 @default.
• W4387245569 creator A5043717032 @default.
• W4387245569 creator A5046355139 @default.
• W4387245569 creator A5049588259 @default.
• W4387245569 creator A5054730003 @default.
• W4387245569 creator A5061933807 @default.
• W4387245569 creator A5073002557 @default.
• W4387245569 creator A5073240939 @default.
• W4387245569 creator A5077641590 @default.
• W4387245569 creator A5077900689 @default.
• W4387245569 creator A5085435765 @default.
• W4387245569 creator A5092189214 @default.
• W4387245569 creator A5092922405 @default.
• W4387245569 date "2023-10-02" @default.
• W4387245569 modified "2023-10-17" @default.
• W4387245569 title "Resistance to PRMT5 Targeted Therapy in Mantle Cell Lymphoma" @default.
• W4387245569 doi "https://doi.org/10.1182/bloodadvances.2023010554" @default.
• W4387245569 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37782774" @default.
• W4387245569 hasPublicationYear "2023" @default.
• W4387245569 type Work @default.
• W4387245569 citedByCount "0" @default.
• W4387245569 crossrefType "journal-article" @default.
• W4387245569 hasAuthorship W4387245569A5000554189 @default.
• W4387245569 hasAuthorship W4387245569A5000870253 @default.
• W4387245569 hasAuthorship W4387245569A5006168813 @default.
• W4387245569 hasAuthorship W4387245569A5010045617 @default.
• W4387245569 hasAuthorship W4387245569A5011478803 @default.
• W4387245569 hasAuthorship W4387245569A5012097098 @default.
• W4387245569 hasAuthorship W4387245569A5012846289 @default.
• W4387245569 hasAuthorship W4387245569A5018193992 @default.
• W4387245569 hasAuthorship W4387245569A5021340844 @default.
• W4387245569 hasAuthorship W4387245569A5037733702 @default.
• W4387245569 hasAuthorship W4387245569A5038777438 @default.
• W4387245569 hasAuthorship W4387245569A5041781866 @default.
• W4387245569 hasAuthorship W4387245569A5043717032 @default.
• W4387245569 hasAuthorship W4387245569A5046355139 @default.
• W4387245569 hasAuthorship W4387245569A5049588259 @default.
• W4387245569 hasAuthorship W4387245569A5054730003 @default.
• W4387245569 hasAuthorship W4387245569A5061933807 @default.
• W4387245569 hasAuthorship W4387245569A5073002557 @default.
• W4387245569 hasAuthorship W4387245569A5073240939 @default.
• W4387245569 hasAuthorship W4387245569A5077641590 @default.
• W4387245569 hasAuthorship W4387245569A5077900689 @default.
• W4387245569 hasAuthorship W4387245569A5085435765 @default.
• W4387245569 hasAuthorship W4387245569A5092189214 @default.
• W4387245569 hasAuthorship W4387245569A5092922405 @default.
• W4387245569 hasBestOaLocation W43872455691 @default.
• W4387245569 hasConcept C104317684 @default.
• W4387245569 hasConcept C111819275 @default.
• W4387245569 hasConcept C127561419 @default.
• W4387245569 hasConcept C1491633281 @default.
• W4387245569 hasConcept C153911025 @default.
• W4387245569 hasConcept C185592680 @default.
• W4387245569 hasConcept C199835354 @default.
• W4387245569 hasConcept C203014093 @default.
• W4387245569 hasConcept C2777525834 @default.
• W4387245569 hasConcept C2779338263 @default.
• W4387245569 hasConcept C29537977 @default.
• W4387245569 hasConcept C33288867 @default.
• W4387245569 hasConcept C502942594 @default.
• W4387245569 hasConcept C54355233 @default.
• W4387245569 hasConcept C55493867 @default.
• W4387245569 hasConcept C62112901 @default.
• W4387245569 hasConcept C62478195 @default.
• W4387245569 hasConcept C81885089 @default.
• W4387245569 hasConcept C86554907 @default.
• W4387245569 hasConcept C86803240 @default.
• W4387245569 hasConcept C91965660 @default.
• W4387245569 hasConcept C95444343 @default.
• W4387245569 hasConceptScore W4387245569C104317684 @default.
• W4387245569 hasConceptScore W4387245569C111819275 @default.
• W4387245569 hasConceptScore W4387245569C127561419 @default.
• W4387245569 hasConceptScore W4387245569C1491633281 @default.
• W4387245569 hasConceptScore W4387245569C153911025 @default.
• W4387245569 hasConceptScore W4387245569C185592680 @default.
• W4387245569 hasConceptScore W4387245569C199835354 @default.
• W4387245569 hasConceptScore W4387245569C203014093 @default.
• W4387245569 hasConceptScore W4387245569C2777525834 @default.
• W4387245569 hasConceptScore W4387245569C2779338263 @default.
• W4387245569 hasConceptScore W4387245569C29537977 @default.
• W4387245569 hasConceptScore W4387245569C33288867 @default.
• W4387245569 hasConceptScore W4387245569C502942594 @default.
• W4387245569 hasConceptScore W4387245569C54355233 @default.
• W4387245569 hasConceptScore W4387245569C55493867 @default.
• W4387245569 hasConceptScore W4387245569C62112901 @default.
• W4387245569 hasConceptScore W4387245569C62478195 @default.
• W4387245569 hasConceptScore W4387245569C81885089 @default.

• next